

For the use of Registered Medical Practitioner or Hospital use or Laboratory use only

Bricanyl® Durules®

Sustained release tablets of terbutaline Sulphate

Composition

Each sustained release tablet contains:

Terbutaline Sulphate I.P. 5 mg & 7.5 mg.

Description: The sustained release mechanism in terbutaline (Bricanyl® Durules®) is based on the matrix principle of drug release. The matrix is made of an inert polymer and is a three-dimensional system of pores into which the active drug terbutaline is packed. The interface between the active drug and the surrounding gastrointestinal fluids is thus limited; only the drug on the surface of the durules that is in contact with the gastrointestinal fluids dissolves at first. The dissolution of the drug on the surface leaves behind cavities through which the gastrointestinal fluids have access to deeper parts of the durules, from where the drug is gradually released. Thus the absorption phase is prolonged and the preparation may be administered every 12th hour (b.i.d) with the maintenance of a good bronchospasmolytic effect round the clock. The problem of morning dipping can thus be overcome with Bricanyl® Durules®. With Bricanyl® Durules®, excessive peak plasma concentrations of the drug are avoided, thus minimising dose related side effects. The b.i.d. dosage enhances patient compliance. The empty matrix remaining after all the drug has been released passes down the intestine and may be excreted unchanged.

Indications: For the relief of bronchospasm in bronchial asthma, chronic bronchitis, emphysema and other diseases of the lung where bronchoconstriction is a complicating factor.

Precautions: Patients with thyrotoxicosis should use terbutaline with caution. Terbutaline should be given with care-as any other sympathomimetic amine - to patients with cardiovascular diseases or diabetes and to patients with a record of hypersensitivity to sympathomimetic amines.

Adverse Effects: The frequency of side effects with oral terbutaline is low. Those recorded e.g. tremor and palpitations are characteristic of all sympathomimetic amines. Tremor diminishes on continued treatment. Tremor and palpitations subside if the dose is lowered.

Dosage Adults: One Bricanyl® Durules® 5 mg or 7.5 mg b.i.d. **Children:** One Bricanyl® Durules® 5 mg b.i.d. Bricanyl® Durules® should not be divided, crushed or chewed but must be swallowed whole together with half a glass of fluid.

Presentation: Bricanyl® Durules® 5.0 mg & 7.5 mg, strip of 10 tablets

For further information please contact:

AstraZeneca Pharma India Ltd.
Bellary Road, Hebbal
Bangalore – 560 024